Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease

NCT07697547 · clinicaltrials.gov ↗

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Disease (IBD)
Crohn's Disease

Interventions

DRUG: Upadacitinib
DRUG: Ustekinumab (UST)

Sponsor

Shanghai 10th People's Hospital

Collaborators

[object Object]
[object Object]